StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) shareholders

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.77−0.01 (-0.10%)

Close on Nov 18, 2026Market cap $1.37BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
144M of 140M shares
Institutional holders
328
55 new, 28 sold out
Net institutional buying
34M
In Q2 2026
Insider trades, 12 months
1 buys · 19 sales
Net sold $868.72K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
ARK Investment Management LLC
Joint filing with Catherine D. Wood (12.27%)
14,207,32412.27%13G (passive) amendmentDec 31, 2025
Catherine D. Wood
Joint filing with ARK Investment Management LLC (11.10%)
11,919,17811.10%13G (passive) amendmentSep 30, 2025
BlackRock, Inc.8,453,0148.20%13G (passive) amendmentMar 31, 2025
State Street Corporation7,809,0605.60%13G (passive)Sep 30, 2026
Vanguard Portfolio Management6,266,0075.30%13G (passive)Mar 31, 2026
Vanguard Capital Management5,945,5715.03%13G (passive)Mar 31, 2026
Contrarius Investment Management Ltd
Joint filing with Contrarius Investment Management (Bermuda) Ltd (5.50%)
5,889,9365.50%13G (passive)Sep 30, 2025
The Goldman Sachs Group, Inc.
Joint filing with Goldman Sachs & Co. LLC (5.10%)
5,498,2625.10%13G (passive)Sep 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NTLAValueChange% of portfolio
ARK Investment Management LLC16,875,68412.04%$285.54M+2,366,4371.85%
BlackRock, Inc.15,409,02311.00%$260.72M+3,253,2170.00%
State Street Corp9,234,9876.59%$156.26M+2,312,3110.00%
Vanguard Portfolio Management LLC7,332,4015.23%$124.06M+1,109,0760.01%
D. E. Shaw & Co., Inc.6,443,3234.60%$109.02M+715,1460.05%
Vanguard Capital Management LLC6,028,5864.30%$102.00M+944,4810.00%
Two Sigma Investments, LP5,235,3483.74%$88.58M+529,4470.06%
FMR LLC4,773,0343.41%$80.76M+2,705,8120.00%
Ra Capital Management, L.P.4,526,9263.23%$76.60MNew0.67%
Regeneron Pharmaceuticals, Inc.3,702,9952.64%$62.65M–35.35%
Geode Capital Management, LLC3,631,0612.59%$61.45M+779,5890.00%
Arrowstreet Capital, Limited Partnership3,280,7602.34%$55.51M+1,883,5170.02%
Sumitomo Mitsui Trust Holdings, Inc.2,897,5292.07%$49.03M+924,4680.03%
Nikko Asset Management Americas, Inc.2,897,5292.07%$49.03M+924,4680.63%
Dimensional Fund Advisors LP2,602,9441.86%$44.04M+284,8340.01%
Goldman Sachs Group Inc2,264,4711.62%$38.31M+636,2300.00%
UBS Group AG2,152,9121.54%$36.43M−536,5740.00%
Voloridge Investment Management, LLC2,066,3561.47%$34.96M+454,8220.15%
Contrarius Group Holdings Ltd1,955,2281.40%$33.08M+43,3891.52%
Jupiter Asset Management Ltd1,849,5071.32%$31.29M+68,4440.16%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026328144M100.0%55 / 14081 / 2838M5M
Q1 2026304111M78.9%62 / 12863 / 4630M10M
Q4 2025293104M74.4%67 / 9887 / 4821M21M
Q3 2025284105M74.7%45 / 10279 / 3917M13M
Q2 2025281100M71.5%42 / 11188 / 5314M15M
Q1 2025295101M72.4%51 / 9496 / 4612M9M
Q4 202429499M70.9%64 / 12768 / 4925M18M
Q3 202428494M67.0%43 / 11286 / 4719M7M
Q2 202429191M64.8%48 / 11488 / 378M14M
Q1 202428497M69.3%37 / 11688 / 4215M6M
Q4 202329388M63.1%48 / 12378 / 3612M4M
Q3 202328580M57.3%34 / 12066 / 386M3M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

222 funds held NTLA in Q2 2026, 73% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of NTLAValue% of fundAs of
ARK Innovation ETF9,987,3157.13%$106.66M1.92%Jul 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF5,756,4634.11%$97.40M0.91%Jun 30, 2026
Vanguard Total Stock Market Index Fund4,286,2003.06%$72.52M0.00%Jun 30, 2026
iShares Russell 2000 ETF3,524,6142.52%$59.64M0.07%Jun 30, 2026
Vanguard Small-Cap Index Fund3,106,2422.22%$52.56M0.03%Jun 30, 2026
ARK Genomic Revolution ETF2,667,0621.90%$28.48M1.83%Jul 31, 2026
Select Biotechnology Portfolio1,914,8331.37%$26.94M0.51%May 31, 2026
Vanguard Small-Cap Growth Index Fund1,798,1891.28%$30.43M0.06%Jun 30, 2026
Vanguard Extended Market Index Fund1,604,9871.15%$27.16M0.03%Jun 30, 2026
Fidelity Small Cap Index Fund1,478,6521.06%$15.79M0.05%Jul 31, 2026
Select Pharmaceuticals Portfolio1,266,2000.90%$17.82M1.19%May 31, 2026
iShares Russell 2000 Value ETF1,264,6200.90%$21.40M0.15%Jun 30, 2026
iShares Biotechnology ETF938,7150.67%$15.88M0.17%Jun 30, 2026
Vanguard Strategic Equity Fund827,4980.59%$14.00M0.12%Jun 30, 2026
Federated Hermes MDT Small Cap Core Fund820,2430.59%$8.76M0.39%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
John M. LeonardPresident and CEO, Director1,196,4790.85%Nov 3, 2026
Jing L. MarantzEVP, Chief Medical Officer199,8220.14%Oct 28, 2026
Michael P. DubeVP, Chief Accounting Officer65,0220.05%Oct 6, 2026
Edward J. Dulac IIIEVP, Chief Financial Officer148,1750.11%Jul 24, 2026
Birgit C. SchultesEVP, Chief Scientific Officer137,7330.10%Mar 3, 2026
James BastaEVP, General Counsel156,7940.11%Mar 3, 2026
David LebwohlEVP, Chief Medical Officer131,1920.09%Mar 3, 2026
Eliana ClarkEVP, Chief Technical Officer93,8640.07%Mar 3, 2026
Derek HicksEVP, Chief Business Officer59,8780.04%Jan 7, 2025
Laura Sepp-LorenzinoEVP, Chief Scientific Officer77,3880.06%Jan 7, 2025
Brian GoffDirector32,6090.02%Jun 10, 2026
Muna BhanjiDirector36,4030.03%Jun 10, 2026
Georgia KerestyDirector41,0830.03%Jun 10, 2026
Fred E. CohenDirector216,6530.15%Jun 10, 2026
Frank VerwielDirector35,1480.03%Jun 10, 2026
Jesse GoodmanDirector33,5590.02%Jun 10, 2026
William J. ChaseDirector143,8930.10%Jun 10, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
John M. Leonard
President and CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−9,000$11.99$107.91K1,138,064
Jing L. Marantz
EVP, Chief Medical Officer
Oct 26, 2026Award+199,822––199,822
Michael P. Dube
VP, Chief Accounting Officer
Oct 2, 2026Sale−1,864$12.43$23.17K65,022
John M. Leonard
President and CEO, Director
Aug 21, 2026Sale(10b5-1 plan)−2,785$13.00$36.21K1,147,064
John M. Leonard
President and CEO, Director
Aug 20, 2026Sale(10b5-1 plan)−19,890$12.60$250.61K1,149,849
Edward J. Dulac III
EVP, Chief Financial Officer
Jul 22, 2026Sale−8,111$11.25$91.25K148,175
Edward J. Dulac III
EVP, Chief Financial Officer
Jul 2, 2026Sale(10b5-1 plan)−4,677$18.00$84.19K156,286
Michael P. Dube
VP, Chief Accounting Officer
Jul 1, 2026Sale−2,641$16.78$44.32K66,886
Fred E. Cohen
Director
Jun 9, 2026Award+9,200––216,653
Jesse Goodman
Director
Jun 9, 2026Award+9,200––33,559
Brian Goff
Director
Jun 9, 2026Award+9,200––32,609
Georgia Keresty
Director
Jun 9, 2026Award+9,200––41,083
Frank Verwiel
Director
Jun 9, 2026Award+9,200––35,148
Muna Bhanji
Director
Jun 9, 2026Award+9,200––36,403
William J. Chase
Director
Jun 9, 2026Award+9,200––143,893
James Basta
EVP, General Counsel
Mar 2, 2026Sale−1,211$13.78$16.69K156,794
Eliana Clark
EVP, Chief Technical Officer
Mar 2, 2026Sale−607$13.78$8.36K93,864
Edward J. Dulac III
EVP, Chief Financial Officer
Mar 1, 2026Award+61,280––160,963
John M. Leonard
President and CEO, Director
Mar 1, 2026Award+156,400––1,169,739
Birgit C. Schultes
EVP, Chief Scientific Officer
Mar 1, 2026Award+39,200––137,733
James Basta
EVP, General Counsel
Mar 1, 2026Award+46,080––158,005
Eliana Clark
EVP, Chief Technical Officer
Mar 1, 2026Award+7,353––94,471
Michael P. Dube
VP, Chief Accounting Officer
Mar 1, 2026Award+17,250––69,527
David Lebwohl
EVP, Chief Medical Officer
Mar 1, 2026Award+9,943––131,192
David Lebwohl
EVP, Chief Medical Officer
Jan 5, 2026Sale−11,903$9.21$109.63K121,249
Michael P. Dube
VP, Chief Accounting Officer
Jan 5, 2026Sale−2,989$9.21$27.53K52,277
Edward J. Dulac III
EVP, Chief Financial Officer
Jan 5, 2026Sale−6,379$9.21$58.75K99,683
James Basta
EVP, General Counsel
Jan 5, 2026Sale−10,397$9.21$95.76K101,528
John M. Leonard
President and CEO, Director
Jan 5, 2026Sale−34,146$9.21$314.48K1,013,339
Fred E. Cohen
Director
Jan 5, 2026Buy+150,000$9.35$1.40M207,453
Eliana Clark
EVP, Chief Technical Officer
Jan 5, 2026Sale−9,515$9.21$87.63K87,118
Birgit C. Schultes
EVP, Chief Scientific Officer
Jan 5, 2026Sale−8,508$9.21$78.36K98,533
John M. Leonard
President and CEO, Director
Dec 12, 2025Option exercise+8,557$6.83$58.44K1,047,485
John M. Leonard
President and CEO, Director
Dec 11, 2025Sale(10b5-1 plan)−49,959$9.49$474.11K1,077,115
John M. Leonard
President and CEO, Director
Dec 11, 2025Sale(10b5-1 plan)−32,832$9.47$310.92K1,044,283
John M. Leonard
President and CEO, Director
Dec 11, 2025Sale(10b5-1 plan)−5,355$9.59$51.35K1,038,928
John M. Leonard
President and CEO, Director
Dec 11, 2025Option exercise+49,959$6.83$341.22K1,127,074
Michael P. Dube
VP, Chief Accounting Officer
Oct 1, 2025Sale−1,871$17.38$32.52K55,266
Birgit C. Schultes
EVP, Chief Scientific Officer
Oct 1, 2025Sale−31$17.38$539105,184
William J. Chase
Director
Aug 20, 2025Buy+100,000$10.03$1.00M134,693
Edward J. Dulac III
EVP, Chief Financial Officer
Jul 23, 2025Sale−7,462$14.02$104.62K106,062
Michael P. Dube
VP, Chief Accounting Officer
Jul 2, 2025Sale−2,503$9.95$24.90K57,137
Eliana Clark
EVP, Chief Technical Officer
Jul 1, 2025Sale−1,022$9.82$10.04K95,369
Jesse Goodman
Director
Jul 1, 2025Sale(10b5-1 plan)−1,547$9.23$14.28K24,359
Jesse Goodman
Director
Jun 30, 2025Sale(10b5-1 plan)−1,547$9.56$14.79K25,906
Georgia Keresty
Director
Jun 11, 2025Award+8,000––31,883
Fred E. Cohen
Director
Jun 11, 2025Award+8,000––57,453
Jesse Goodman
Director
Jun 11, 2025Award+8,000––27,453
Muna Bhanji
Director
Jun 11, 2025Award+8,000––27,203
William J. Chase
Director
Jun 11, 2025Award+8,000––34,693
Brian Goff
Director
Jun 11, 2025Award+8,000––23,409
Frank Verwiel
Director
Jun 11, 2025Award+8,000––25,948
Muna Bhanji
Director
Apr 29, 2025Sale(10b5-1 plan)−265$8.50$2.25K19,203
James Basta
EVP, General Counsel
Mar 4, 2025Sale−2,572$8.99$23.12K111,925
Eliana Clark
EVP, Chief Technical Officer
Mar 4, 2025Sale−679$8.99$6.10K95,369
James Basta
EVP, General Counsel
Mar 1, 2025Award+40,000––114,497
Edward J. Dulac III
EVP, Chief Financial Officer
Mar 1, 2025Award+47,200––113,524
Eliana Clark
EVP, Chief Technical Officer
Mar 1, 2025Award+32,000––96,048
John M. Leonard
President and CEO, Director
Mar 1, 2025Award+136,000––1,077,115
Birgit C. Schultes
EVP, Chief Scientific Officer
Mar 1, 2025Award+37,600––105,215

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
32.31%
44M shares short
Days to cover
11.1
At 4M shares a day
Change since last report
-0.2%
From 44M shares
Short volume, 20 days
49.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Intellia Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 399,250 shares on Sep 30, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
John M. Leonard
Officer, Director
Nov 2, 20269,000$113.40KNov 2, 2026Stock Option Exercise
Eliana Clark
Officer
Oct 5, 202657,750$736.31KOct 5, 2026Stock Option Exercise
John M. Leonard
Officer, Director
Aug 20, 202622,675$293.64KAug 20, 2026Stock Option Exercise
Edward J. Dulac III
Officer
Jul 2, 20264,677$80.63KJul 2, 2026Restricted Stock Units
John M. Leonard
Officer, Director
Dec 11, 202588,146$822.40KDec 11, 2025Restricted Vesting
Laura Sepp-Lorenzino
Officer
Jan 8, 20242,275$64.11KJan 8, 2024Restricted Stock Unit
John F. Crowley
Former Director
Dec 7, 202332,791$506.70KDec 6, 2023Option Exercise
Muna Bhanji
Director
Jul 31, 2023265$11.22KJul 31, 2023Restricted Stock
Muna Bhanji
Director
Jul 6, 20231,867$73.38KJul 6, 2023Restricted Stock
Eliana Clark
Officer
Jun 20, 20235,000$225.00KJun 20, 2023Stock Option Exercise

Congress trades

10 trades in Intellia Therapeutics reported by 2 members of the House

MemberTypeTradedAmountFiled
Donald Sternoff Beyer Jr
VA08 · joint account
SoldFeb 28, 2022$15KMar 3, 2022
Donald Sternoff Honorable Beyer Jr
VA08 · joint account
SoldOct 29, 2021$1K–15KOct 30, 2021
Donald Sternoff Honorable Beyer Jr
VA08 · joint account
SoldSep 20, 2021$1K–15KOct 1, 2021
Donald Sternoff Honorable Beyer Jr
VA08 · joint account
SoldJul 21, 2021$1K–15KAug 7, 2021
Donald Sternoff Honorable Beyer Jr
VA08 · joint account
SoldJan 15, 2021$1K–15KJan 31, 2021
Donald Sternoff Beyer Jr
VA08 · joint account
BoughtNov 18, 2020$1K–15KDec 1, 2020
Donald Sternoff Beyer Jr
VA08 · joint account
SoldAug 26, 2020$1K–15KSep 6, 2020
Donald Sternoff Beyer Jr
VA08 · joint account
BoughtJul 10, 2020$1K–15KAug 9, 2020
Donald Sternoff Beyer Jr
VA08 · joint account
BoughtJan 14, 2020$1K–15KFeb 22, 2020
Donald Sternoff Beyer Jr
VA08 · joint account
BoughtDec 9, 2019$1K–15KDec 14, 2019

See a number that looks wrong?